Quick Answer
Zymeworks Inc. reported Stockholders Equity of $268.50 million for the year ending 2025.
- Zymeworks Inc. showed a decrease of -20.7% in Stockholders Equity from 2024 to 2025.
- This data is from Zymeworks Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $377.15 million | Q2 2021: $321.47 million | Q3 2021: $278.93 million | Q1 2022: $282.44 million | Q2 2022: $222.28 million | Q3 2022: $179.76 million | Q1 2023: $473.54 million | Q2 2023: $448.92 million | Q3 2023: $424.34 million | Q1 2024: $438.00 million | Q2 2024: $406.16 million | Q3 2024: $366.98 million | Q1 2025: $324.97 million | Q2 2025: $334.51 million | Q3 2025: $320.06 million.
- Over the full 7 years of available data (2019 to 2025), Zymeworks Inc.'s Stockholders Equity has grown by 9.3%.
- Historical annual values: Fiscal year 2025: $268.50 million | Fiscal year 2024: $338.77 million | Fiscal year 2023: $464.81 million | Fiscal year 2022: $492.96 million | Fiscal year 2021: $249.09 million | Fiscal year 2020: $409.92 million | Fiscal year 2019: $245.68 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: